Prof. Dr. Lütfiye Demir

Medical areas of interest stated by the doctor on the institution profile. Source: medicana.com.tr.

Experience

• 2002-2008Dr.Ar. Gör.- İstanbul Üniversitesi Tıp Fakültesi İç Hastalıkları A.B.Dmedicana.com.tr
• 2009-2012Uzm. Dr. Ar. Gör. - İzmir Atatürk Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji Kliniğimedicana.com.tr
• 2013-2014Uzm. Dr. - Aydın Atatürk Devlet Hastanesimedicana.com.tr
• 2015-2016Doç. Dr.- Medical Park Trabzon Hastanesimedicana.com.tr
• 2016-2021Doç.Dr. - Eskişehir Osmangazi Üniv. Tıp Fakültesi İç Hastalıkları/ Tıbbi Onkolojimedicana.com.tr

Education

• 2001İstanbul Üniversitesi Tıp Fakültesimedicana.com.tr
• 2008İstanbul Üniversitesi Tıp Fakültesimedicana.com.tr

• SpecialtyMedical Oncologymedicana.com.trFrom source
• Department name at the sourceMedikal Onkolojimedicana.com.trFrom source
• InstitutionMedicana International İzmirmedicana.com.trFrom source
• Publications165 publicationsmedicana.com.tr profile pageFrom source
• Last synchronised7 November 2026 03:17https://www.medicana.com.tr/hekim-detay/12866/lutfiye-demirmedicana.com.tr

1. E. Ulusal bilimsel toplantılarda sunulan ve bildiri kitaplarında basılan bildiriler:

   Source: medicana.com.tr profile page

2. B. Uluslararası bilimsel toplantılarda sunulan ve bildiri kitabında (Proceedings) basılan bildiriler:

   Source: medicana.com.tr profile page

3. A1. Demir L, Somali I, Oktay Tarhan M, Erten C, Ellidokuz H, Can A, Dirican A, Vedat Bayoglu I. The toxicity and efficacy of Nordic-FLOX regimen as adjuvant treatment of stage III colon cancer. J BUON 2011;16(4):682-8.

   Source: medicana.com.tr profile page

4. A2. Demir L, Erten C, Yigit SC, Can A, Dirican A, Bayoglu V, Kucukzeybek Y, Somali I, Tarhan MO. Intramammary lymph node metastasis in a patient with ovarian carcinoma and a brief review of the literature. Contemp Oncol (Pozn). 2012;16(2):108-10.

   Source: medicana.com.tr profile page

5. A3. Yigit S, Demir L, Tarhan MO, Cabuk FK, Ellidokuz H, Erten C, Somali I, Dirican A, Cakalagaoglu F. The clinicopathological significance of Bax and Bcl-2 protein expression with tumor infiltrating lymphocytes in ovarian carcinoma. Neoplasma2012;59(5):475-85.

   Source: medicana.com.tr profile page

6. A4. Demir L, Can A, Dirican A, Bayoğlu V, Rezanko TA, Akyol M, Kucukzeybek Y, Erten C, Tarhan MO. Malignant fibrous histiocytoma of the spermatic cord in a patient with polycystic kidney disease; review of the literature. Clin Genitourin Cancer. 2012;10(4):280-3.

   Source: medicana.com.tr profile page

7. A5. Kaplan MA, Isikdogan A, Koca D, Kucukoner M, Gumusay O, Yildiz R, Dayan A, Demir L, Geredeli C, Kocer M, Arslan UY, Inal A, Unal OU, Mert AG, Bilici M, Ozkan M, Elkiran ET, Yaman S, Durnalı AG, Suner A, Alici S, Tarhan MO, Boruban C, Urakci Z, Buyukberber S. Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology). Oncology. 2012;83(3):141-50.

   Source: medicana.com.tr profile page

8. A6. Demir L, Erten C, Somali I, Can A, Dirican A, Bayoglu V, Kucukzeybek Y, Altinboga AA, Ermete M, Oztop RM, Tarhan MO. Metastases of renal cell carcinoma to the larynx and thyroid: Two case reports on metastasis developing years after nephrectomy. Can Urol Assoc J. 2012;6(5):E209-12.

   Source: medicana.com.tr profile page

9. A7. Kucukzeybek Y, Dirican A, Erten C, Somali I, Can A, Demir L, Bayoglu IV, Akyol M, Medeni M, Tarhan MO. Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer. Asian Pac J Cancer Prev. 2012;13(6):2771-4.

   Source: medicana.com.tr profile page

10. A8. Kamali S, Artim-Esen B, Erer B, Ozdener L, Gul A, Ocal L, Aral O, Inanc M. Re-evaluation of 129 patients with systemic necrotizing vasculitides by using classification algorithm according to consensus methodology. Clin Rheumatol. 2012;31(2):325-8.

    Source: medicana.com.tr profile page